Plant Comparison
Hawthorn vs Motherwort
A side-by-side comparison of two medicinal plants — every documented constituent, action, use, safety note and cited source, assembled automatically from the Omnia Sana database.
At a glance
Hawthorn and Motherwort: they share 5 indicated uses (arthritis / joint pain, cardiovascular / heart health, inflammation (general), …); 3 pharmacological actions in common.
Evidence face-off — shared uses
| Condition | Hawthorn | Motherwort | Verdict |
|---|---|---|---|
| Arthritis / joint pain | 1/10 | 1/10 | Comparable evidence |
| Cardiovascular / heart health | 1/10 | 2/10 | Comparable evidence |
| Inflammation (general) | 1/10 | 1/10 | Comparable evidence |
| Insomnia / sleeplessness | 1/10 | 2/10 | Comparable evidence |
| Skin irritation | 1/10 | 1/10 | Comparable evidence |
Evidence scores (1–10) are computed from the tier of each cited source. “Comparable” means the two scores are within one point. Follow a score to its detailed sources.
Key Constituents
Principal cardioprotective and antioxidant polyphenols characterised by chemical profiling of leaf, flower and fruit.
Contribute to the vasoactive and antioxidant effects, the basis for extract standardisation.
Leonurine and related iridoid/alkaloid-type constituents are considered the principal cardioactive and uterotonic compounds.
Antioxidant constituents contributing to the plant's anti-inflammatory activity.
Bitter diterpenes, shared with related Lamiaceae bitters, contributing to the traditional digestive and cardiac reputation.
Pharmacological Actions
Traditional & Indicated Uses
inferred from anti-inflammatory action
inferred from anticancer action
inferred from anti-inflammatory action
inferred from sedative action
inferred from anti-inflammatory action
inferred from anti-inflammatory action
inferred from sedative action
inferred from antispasmodic action
Safety, Cautions & Contraindications
Generally well tolerated. Hawthorn should not replace prescribed cardiac medications without medical supervision. May potentiate the effects of cardiac glycosides (digoxin), antihypertensive drugs, and coronary dilators. Not recommended during pregnancy and breastfeeding due to insufficient safety data. Mild side effects (nausea, dizziness, GI upset) occasionally reported.
Duke (2002) rates hawthorn as +++ — one of the most clinically supported cardiovascular herbs. Clinical evidence (score 2) supports its use for decreasing cardiac output (NYHA functional Stage II heart failure), as recognized by Commission E. Key activities include vasodilation, positive inotropic effects, and antioxidant protection of vascular tissue. Dose: 160–900 mg standardized leaf/flower extract (containing 18.75% oligomeric proanthocyanidins) daily. Duke emphasizes that hawthorn should not replace conventional heart failure therapy, and therapeutic effects may take 4–8 weeks to emerge. Mild interactions with cardiac glycosides (digitalis) are possible (Duke, 2002).
Contraindicated in pregnancy (uterine stimulant). Avoid in heavy menstrual bleeding. May enhance anticoagulant and antihypertensive drug effects. Avoid in thyroid disorders. Generally well tolerated in normal doses for short-term use.
Duke (2002) rates motherwort as ++ and notes hypotensive, cardiotonic (negative chronotropic), anti-aggregant, and sedative activities at the experimental level (score 1). The plant is traditionally used for heart palpitations, hypertension, and menstrual regulation in European herbalism. Duke emphasizes strong safety caution: motherwort has documented oxytocic (uterine-stimulating) activity and is strictly contraindicated in pregnancy. It may also enhance the effects of cardiac medications and sedatives (Duke, 2002).
External Ids
Botanical Description
Small deciduous tree or large shrub, densely thorny, with deeply lobed, glossy leaves (more deeply cut than midland hawthorn). Clusters of small, five-petalled white flowers with a strong, musky scent appear in spring ('May blossom'), followed by small red berries (haws), each containing a single seed (nutlet) - the origin of the species name monogyna.[4]
Tall, upright perennial herb with deeply palmately lobed lower leaves (giving a lion's-paw appearance, the source of the genus name) and progressively less-divided upper leaves. Small, pink to pale purple, spiny-toothed, two-lipped flowers are borne in dense whorls up the square stem.[1]
Habitat
One of the commonest hedgerow and scrub trees of Europe, growing in hedgerows, woodland edges, scrub and pasture on a wide range of soils; native to Europe, North Africa and Western Asia.[4]
Grows on waste ground, roadsides, hedgerows and near old dwellings; native to Central Asia and southeastern Europe and long naturalised across Europe and North America.[1]
Harvesting
Flowers are picked as they open in May, leaves are picked with the young flowering shoots, and the ripe red berries (haws) are gathered in autumn after the first frosts soften them slightly; all three parts are traditionally combined.[4]
The flowering aerial parts (leaf, stem and flower) are cut in summer as the plant comes into flower, and dried in a warm, shaded, airy place.[1]
Traditional Uses
Common hawthorn shares the same long cardiovascular and calming tradition as midland hawthorn, used across European herbal medicine as a heart tonic for mild circulatory complaints, palpitations and nervous tension, and remains one of the most clinically studied cardiovascular botanicals.[4]
Motherwort has a long European and Asian herbal tradition, reflected in its name, as a gynaecological and cardiac tonic, traditionally used for heart palpitations and nervous cardiac complaints, menstrual irregularities and cramps, and as a calming nervine for anxiety and to ease childbirth and postpartum recovery.[1, 6]
Preparations
Leaf-and-flower extract standardised to flavonoid or procyanidin content, taken as tablets or capsules; the best-studied clinical form.
Dosage
The EU herbal monograph on Crataegus spp., folium cum flore gives dry extracts in divided daily doses of 240-900 mg (single dose 80-450 mg) or, for one quantified extract, 570-1750 mg daily (single dose 190-350 mg), in adults and elderly. If symptoms persist longer than 2 weeks a doctor should be consulted, and hawthorn is never used as a substitute for prescribed heart medication without medical supervision. Educational reference only, not a prescription.
The EU herbal monograph gives 1-2 g of the comminuted leaf and flower in 150 mL of boiling water as an infusion, up to 4 times daily (maximum 6 g daily), in adults and elderly. Educational reference only, not a prescription.
The EU herbal monograph gives a single dose of 1.5-4.5 g of the comminuted herb for tea preparation, for a daily dose of 3-10 g, in adults and elderly; a 1:5 tincture in 45% V/V ethanol at 2-6 mL three times daily and a liquid extract at 2-4 mL three times daily are also listed. If symptoms persist longer than 4 weeks a healthcare practitioner should be consulted. Not recommended under 18 years. Educational reference only, not a prescription.
References
Drug Class Interactions
Lookalikes Review
References & Sources
- Ez-Zahra Amrati, F., Mssillou, I., Boukhira, S., Djiddi Bichara, M. et al (2024) 'Phenolic Composition of Crataegus monogyna Jacq. Extract and Its Anti-Inflammatory, Hepatoprotective, and Antileukemia Effects', Pharmaceuticals (Basel), 17(6), pp. 786. doi:10.3390/ph17060786 Preclinical
https://doi.org/10.3390/ph17060786 - Lis, M., Szczypka, M., Suszko-Pawłowska, A., Sokół-Łętowska, A. et al (2019) 'Hawthorn (Crataegus monogyna) Phenolic Extract Modulates Lymphocyte Subsets and Humoral Immune Response in Mice', Planta Medica, 86(2), pp. 160-168. doi:10.1055/a-1045-5437 Preclinical
https://doi.org/10.1055/a-1045-5437 - Paun, G., Neagu, E., Albu, C., Alecu, A. et al (2024) 'Antioxidant and Antidiabetic Activity of Crataegus monogyna L. and Cornus mas Fruit Extracts', Molecules, 29(15), pp. 3595. doi:10.3390/molecules29153595 Preclinical
https://doi.org/10.3390/molecules29153595 - Nabavi, S.F., Habtemariam, S., Ahmed, T., Sureda, A., Daglia, M. and Sobarzo-Sanchez, E (2015) 'Polyphenolic Composition of Crataegus monogyna Jacq.: From Chemistry to Medical Applications', Nutrients, 7(9), pp. 7708-7728. doi:10.3390/nu7095361 Meta-analysis / review
https://doi.org/10.3390/nu7095361 - Belabdelli, F., Bekhti, N., Piras, A., Benhafsa, F.M., Ilham, M. and Adil, S (2021) 'Chemical composition, antioxidant and antibacterial activity of Crataegus monogyna leaves' extracts', Natural Product Research, 36(12), pp. 3234-3239. doi:10.1080/14786419.2021.1958215 Preclinical
https://doi.org/10.1080/14786419.2021.1958215 - Jalali, A.S., Hasanzadeh, S. and Malekinejad, H (2012) 'Crataegus monogyna aqueous extract ameliorates cyclophosphamide-induced toxicity in rat testis: stereological evidences', Acta Medica Iranica, 50(1), pp. 1-8. Preclinical
https://scholar.google.com/scholar?q=Crataegus%20monogyna%20aqueous%20extract%20ameliorates%20cyclophosphamide-induced%20toxicity%20in%20rat%20testis%3A%20stereological%20evidences - Martin-Garcia, B., Razola-Diaz, M.D.C., Gomez-Caravaca, A.M., Benitez, G. and Verardo, V (2021) 'Setup of an Ultrasonic-Assisted Extraction to Obtain High Phenolic Recovery in Crataegus monogyna Leaves', Molecules, 26(15), pp. 4536. doi:10.3390/molecules26154536 Preclinical
https://doi.org/10.3390/molecules26154536 - Arslan, R., Bektas, N., Bor, Z. and Sener, E (2014) 'Evaluation of the antithrombotic effects of Crataegus monogyna and Crataegus davisii in the carrageenan-induced tail thrombosis model', Pharmaceutical Biology, 53(2), pp. 275-279. doi:10.3109/13880209.2014.914957 Preclinical
https://doi.org/10.3109/13880209.2014.914957 - Edwards, J.E., Brown, P.N., Talent, N., Dickinson, T.A. and Shipley, P.R (2012) 'A review of the chemistry of the genus Crataegus', Phytochemistry, 79, pp. 5-26. doi:10.1016/j.phytochem.2012.04.006 Meta-analysis / review
https://doi.org/10.1016/j.phytochem.2012.04.006 - Jarzycka, A., Lewinska, A., Gancarz, R. and Wilk, K.A (2013) 'Assessment of extracts of Helichrysum arenarium, Crataegus monogyna, Sambucus nigra in photoprotective UVA and UVB; photostability in cosmetic emulsions', Journal of Photochemistry and Photobiology B: Biology, 128, pp. 50-57. doi:10.1016/j.jphotobiol.2013.07.029 Preclinical
https://doi.org/10.1016/j.jphotobiol.2013.07.029 - Lucconi, G., Chlapanidas, T., Martino, E., Gaggeri, R., Perteghella, S. and Rossi, D (2013) 'Formulation of microspheres containing Crataegus monogyna Jacq. extract with free radical scavenging activity', Pharmaceutical Development and Technology, 19(1), pp. 65-72. doi:10.3109/10837450.2012.752387 Preclinical
https://doi.org/10.3109/10837450.2012.752387 - Zorniak, M., Szydlo, B. and Krzeminski, T.F (2017) 'Crataegus special extract WS 1442: up-to-date review of experimental and clinical experiences', Journal of Physiology and Pharmacology, 68(4), pp. 521-526. Meta-analysis / review
https://scholar.google.com/scholar?q=Crataegus%20special%20extract%20WS%201442%3A%20up-to-date%20review%20of%20experimental%20and%20clinical%20experiences - European Medicines Agency (2016) 'European Union herbal monograph on Crataegus spp., folium cum flore'. Traditional / reference
https://scholar.google.com/scholar?q=European%20Union%20herbal%20monograph%20on%20Crataegus%20spp.%2C%20folium%20cum%20flore - Pittler, M.H., Guo, R. and Ernst, E (2008) 'Hawthorn extract for treating chronic heart failure'. Traditional / reference
https://scholar.google.com/scholar?q=Hawthorn%20extract%20for%20treating%20chronic%20heart%20failure - Royal Botanic Gardens, Kew (n.d.). Available at: https://powo.science.kew.org Traditional / reference
https://powo.science.kew.org - Duke, J.A (2002) 'Handbook of Medicinal Herbs, Second Edition'. Traditional / reference
https://scholar.google.com/scholar?q=Handbook%20of%20Medicinal%20Herbs%2C%20Second%20Edition - Tankanow, R., Tamer, H.R., Streetman, D.S., Smith, S.G., Welton, J.L., Annesley, T., Aaronson, K.D. and Bleske, B.E (2003) 'Interaction study between digoxin and a preparation of hawthorn (Crataegus oxyacantha)', Journal of Clinical Pharmacology, 43(6), pp. 637-642. doi:10.1177/0091270003253417 Randomized trial
https://doi.org/10.1177/0091270003253417 - Pittler, M.H., Guo, R. and Ernst, E (2008) 'Hawthorn extract for treating chronic heart failure', Cochrane Database of Systematic Reviews, 2008(1), pp. CD005312. doi:10.1002/14651858.CD005312.pub2 Meta-analysis / review
https://doi.org/10.1002/14651858.CD005312.pub2 - Pittler, M.H., Guo, R. and Ernst, E (2008) 'Hawthorn extract for treating chronic heart failure', Cochrane Database of Systematic Reviews, 2008(1), pp. CD005312. doi:10.1002/14651858.CD005312.pub2 Meta-analysis / review
https://doi.org/10.1002/14651858.CD005312.pub2 - Ghasemzadeh Rahbardar, M. and Hosseinzadeh, H (2024) 'Therapeutic potential of hypnotic herbal medicines: A comprehensive review', Phytotherapy Research, 38(6), pp. 3037-3059. doi:10.1002/ptr.8201 Meta-analysis / review
https://doi.org/10.1002/ptr.8201 - Block, K.I., Gyllenhaal, C. and Mead, M.N (2004) 'Safety and efficacy of herbal sedatives in cancer care', Integrative Cancer Therapies, 3(2), pp. 128-148. doi:10.1177/1534735404265003 Meta-analysis / review
https://doi.org/10.1177/1534735404265003
- Fierascu, R.C., Fierascu, I., Ortan, A., Fierascu, I.C. and others (2019) 'Leonurus cardiaca L. as a Source of Bioactive Compounds: An Update of the European Medicines Agency Assessment Report (2010)', BioMed Research International, 2019, pp. 4303215. doi:10.1155/2019/4303215 Traditional / reference
https://doi.org/10.1155/2019/4303215 - Wojtyniak, K., Szymanski, M. and Matlawska, I (2013) 'Leonurus cardiaca L. (motherwort): a review of its phytochemistry and pharmacology', Phytotherapy Research, 27(8), pp. 1115-1120. doi:10.1002/ptr.4850 Traditional / reference
https://doi.org/10.1002/ptr.4850 - Kuchta, K., Volk, R.B. and Rauwald, H.W (2013) 'Stachydrine in Leonurus cardiaca, Leonurus japonicus, Leonotis leonurus: detection and quantification by instrumental HPTLC and 1H-qNMR analyses', Pharmazie, 68(7), pp. 534-540. Available at: https://pubmed.ncbi.nlm.nih.gov/23923634/ Preclinical
https://pubmed.ncbi.nlm.nih.gov/23923634/ - Kuchta, K., Volk, R.B. and Rauwald, H.W (2012) 'Leonurus japonicus, Leonurus cardiaca, Leonotis leonurus: a novel HPLC study on the occurrence and content of the pharmacologically active guanidino derivative leonurine', Pharmazie, 67(12), pp. 973-979. Available at: https://pubmed.ncbi.nlm.nih.gov/23346757/ Preclinical
https://pubmed.ncbi.nlm.nih.gov/23346757/ - Koshovyi, O., Raal, A., Kireyev, I., Tryshchuk, N. and others (2021) 'Phytochemical and Psychotropic Research of Motherwort (Leonurus cardiaca L.) Modified Dry Extracts', Plants (Basel), 10(2), pp. 230. doi:10.3390/plants10020230 Preclinical
https://doi.org/10.3390/plants10020230 - Angeloni, S., Spinozzi, E., Maggi, F., Sagratini, G. and others (2021) 'Phytochemical Profile and Biological Activities of Crude and Purified Leonurus cardiaca Extracts', Plants (Basel), 10(2), pp. 195. doi:10.3390/plants10020195 Preclinical
https://doi.org/10.3390/plants10020195 - Sadowska, B., Wieckowska-Szakiel, M., Paszkiewicz, M. and Rozalska, B (2019) 'Molecular Mechanisms of Leonurus cardiaca L. Extract Activity in Prevention of Staphylococcal Endocarditis - Study on in Vitro and ex Vivo Models', Molecules, 24(18), pp. 3318. doi:10.3390/molecules24183318 Preclinical
https://doi.org/10.3390/molecules24183318 - Kuchta, K., Hladikova, J., Thomsen, M., Nguyen, A.D. and others (2025) 'Phenolic and Iridoid Glycosides from Leonurus cardiaca L. and Their Effects on the alpha, delta, and gamma Subtypes of the PPAR System', Molecules, 30(2), pp. 419. doi:10.3390/molecules30020419 Preclinical
https://doi.org/10.3390/molecules30020419 - Pereira, O.R., Catarino, M.D., Afonso, A.F., Silva, A.M.S. and Cardoso, S.M (2019) 'Hepatoprotection of Leonurus cardiaca L., Leonurus japonicus Houtt. and Leonurus sibiricus L', Antioxidants (Basel), 8(8), pp. 267. doi:10.3390/antiox8080267 Preclinical
https://doi.org/10.3390/antiox8080267 - Kuchta, K., Ortwein, J. and Rauwald, H.W (2014) '1H-qNMR for direct quantification of stachydrine in Leonurus japonicus and L. cardiaca', Fitoterapia, 96, pp. 8-17. doi:10.1016/j.fitote.2014.03.023 Preclinical
https://doi.org/10.1016/j.fitote.2014.03.023 - European Medicines Agency (HMPC) (2010) 'Community herbal monograph on Leonurus cardiaca L., herba'. Available at: https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-leonurus-cardiaca-l-herba_en.pdf Traditional / reference
https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-leonurus-cardiaca-l-herba_en.pdf - Kowalchik, C. and Hylton, W (1998) 'Rodale'. Traditional / reference
https://scholar.google.com/scholar?q=Rodale - Prajapati, N.D., Purohit, S.S., Sharma, A.K. and Kumar, T (2003) 'A Handbook of Medicinal Plants'. Traditional / reference
https://scholar.google.com/scholar?q=A%20Handbook%20of%20Medicinal%20Plants - Shang, X. et al (2014) 'The genus Leonurus: traditional uses, phytochemistry and pharmacology', pp. 43--63. Traditional / reference
https://scholar.google.com/scholar?q=The%20genus%20Leonurus%3A%20traditional%20uses%2C%20phytochemistry%20and%20pharmacology - Duke, J.A (2002) 'Handbook of Medicinal Herbs, Second Edition'. Traditional / reference
https://scholar.google.com/scholar?q=Handbook%20of%20Medicinal%20Herbs%2C%20Second%20Edition - Ghasemzadeh Rahbardar, M. and Hosseinzadeh, H (2024) 'Therapeutic potential of hypnotic herbal medicines: A comprehensive review', Phytotherapy Research, 38(6), pp. 3037-3059. doi:10.1002/ptr.8201 Meta-analysis / review
https://doi.org/10.1002/ptr.8201 - Block, K.I., Gyllenhaal, C. and Mead, M.N (2004) 'Safety and efficacy of herbal sedatives in cancer care', Integrative Cancer Therapies, 3(2), pp. 128-148. doi:10.1177/1534735404265003 Meta-analysis / review
https://doi.org/10.1177/1534735404265003
Generated automatically from the Omnia Sana plant database and its cited sources. For educational purposes only — not medical advice. Always consult a qualified practitioner before using medicinal plants.